Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

3(27%)

Results Posted

33%(2 trials)

Phase Distribution

Ph phase_3

27%

Ph phase_4

27%

Ph not_applicable

Ph phase_2

36%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 2Efficacy & side effects

4(36.4%)

Phase 3Large-scale testing

3(27.3%)

Phase 4Post-market surveillance

3(27.3%)

N/ANon-phased studies

1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(6)

Terminated(1)

Other(1)

Detailed Status

Completed6

Recruiting3

Withdrawn1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 24 (36.4%)

Phase 33 (27.3%)

Phase 43 (27.3%)

N/A1 (9.1%)

Trials by Status

recruiting327%

withdrawn19%

completed655%

unknown19%

Recent Activity

3 active trials

Showing 5 of 11

completedphase_2

Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study

NCT05253794

recruitingphase_4

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

NCT06543082

recruitingphase_4

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

NCT04875702

completedphase_3

Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

NCT04160117

recruitingphase_4

Colchicine in Acutely Decompensated HFREF

NCT06286423

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT05253794Phase 2

Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study

Completed

NCT06543082Phase 4

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Recruiting

NCT04875702Phase 4

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Recruiting

NCT04160117Phase 3

Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

Completed

NCT06286423Phase 4

Colchicine in Acutely Decompensated HFREF

Recruiting

NCT04756128Phase 2

Impact of Colchicine and Low-dose Naltrexone on COVID-19

Completed

NCT05459974Phase 3

Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation

Unknown

NCT04130204Phase 2

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

Completed

NCT04139655Not Applicable

Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study

Withdrawn

NCT01985425Phase 3

Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study

Completed

NCT02063997Phase 2

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Completed

All 11 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 11